New antibiotics for bad bugs: where are we?
TLDR
The need of new antibiotics still does not cover the increasing prevalence of antibiotic-resistant bacterial infections, so the management of antimicrobial resistance should also include fostering coordinated actions by all stakeholders, creating policy guidance, support for surveillance and technical assistance.Abstract:
Bacterial resistance to antibiotics is growing up day by day in both community and hospital setting, with a significant impact on the mortality and morbidity rates and the financial burden that is associated. In the last two decades multi drug resistant microorganisms (both hospital- and community-acquired) challenged the scientific groups into developing new antimicrobial compounds that can provide safety in use according to the new regulation, good efficacy patterns, and low resistance profile. In this review we made an evaluation of present data regarding the new classes and the new molecules from already existing classes of antibiotics and the ongoing trends in antimicrobial development. Infectious Diseases Society of America (IDSA) supported a proGram, called “the ′10 × ´20′ initiative”, to develop ten new systemic antibacterial drugs within 2020. The microorganisms mainly involved in the resistance process, so called the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and enterobacteriaceae) were the main targets. In the era of antimicrobial resistance the new antimicrobial agents like fifth generation cephalosporins, carbapenems, monobactams, β-lactamases inhibitors, aminoglycosides, quinolones, oxazolidones, glycopeptides, and tetracyclines active against Gram-positive pathogens, like vancomycin-resistant S. aureus (VRSA) and MRSA, penicillin-resistant streptococci, and vancomycin resistant Enterococcus (VRE) but also against highly resistant Gram-negative organisms are more than welcome. Of these compounds some are already approved by official agencies, some are still in study, but the need of new antibiotics still does not cover the increasing prevalence of antibiotic-resistant bacterial infections. Therefore the management of antimicrobial resistance should also include fostering coordinated actions by all stakeholders, creating policy guidance, support for surveillance and technical assistance.read more
Citations
More filters
Journal ArticleDOI
Update on the antibiotic resistance crisis.
TL;DR: Strains with resistance to multiple antibiotic classes have emerged among major Gram-positive and Gram-negative species including Staphylococcus aureus, Enterococcus spp.
Journal ArticleDOI
Methods for the detection and identification of pathogenic bacteria: past, present, and future
Linda Váradi,Linda Váradi,Jia Lin Luo,David E. Hibbs,John D. Perry,Rosaleen J. Anderson,Sylvain Orenga,Paul W. Groundwater +7 more
TL;DR: The challenges associated with the detection and identification of pathogenic bacteria are highlighted, by providing an introduction to the techniques currently used, as well as newer techniques that are in development.
Journal ArticleDOI
Treating infections caused by carbapenemase-producing Enterobacteriaceae
Leonidas S. Tzouvelekis,Antonios Markogiannakis,Evangelia-Theophano Piperaki,Maria Souli,George L. Daikos +4 more
TL;DR: Clinical studies review 20 clinical studies that provided the necessary information regarding isolate and patient characteristics and treatment schemes, as well as a clear assessment of outcome indicate that treatment with a single in vitro active agent resulted in mortality rates not significantly different from that observed in patients treated with no active therapy.
Journal ArticleDOI
Carvacrol and human health: A comprehensive review.
Mehdi Sharifi-Rad,Elena Maria Varoni,Marcello Iriti,Miquel Martorell,William N. Setzer,María del Mar Contreras,Bahare Salehi,Azam Soltani-Nejad,Sadegh Rajabi,Mercedeh Tajbakhsh,Javad Sharifi-Rad,Javad Sharifi-Rad +11 more
TL;DR: The present review illustrates the state‐of‐the‐art studies on the antimicrobial, antioxidant, and anticancer properties of CV.
References
More filters
Journal ArticleDOI
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher,George H. Talbot,John S. Bradley,John S. Bradley,John E. Edwards,John E. Edwards,David N. Gilbert,Louis B. Rice,Louis B. Rice,Michael Scheld,Brad Spellberg,Brad Spellberg,John G. Bartlett +12 more
TL;DR: An update on potentially effective antibacterial drugs in the late-stage development pipeline is provided, in the hope of encouraging collaboration between industry, academia, the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention work productively together.
Journal ArticleDOI
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
Brad Spellberg,Robert Guidos,David N. Gilbert,John S. Bradley,John S. Bradley,Helen W. Boucher,W. Michael Scheld,John G. Bartlett,John E. Edwards +8 more
TL;DR: If the antimicrobial resistance crisis is to be addressed, a concerted, grassroots effort led by the medical community will be required and could mean a literal return to the preantibiotic era for many types of infections.
Journal ArticleDOI
Carbapenems: Past, Present, and Future
Krisztina M. Papp-Wallace,Andrea Endimiani,Andrea Endimiani,Andrea Endimiani,Magdalena A. Taracila,Robert A. Bonomo +5 more
TL;DR: The current “state of the art” of carbapenem antibiotics and their role in the antimicrobial armamentarium are summarized and the medicinal chemist is urged to continue development of these versatile and potent compounds.
Related Papers (5)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A-P Magiorakos,Arjun Srinivasan,R B Carey,Yehuda Carmeli,Matthew E. Falagas,Matthew E. Falagas,Christian G. Giske,Stéphan Juergen Harbarth,Janet F. Hindler,Gunnar Kahlmeter,Barbro Olsson-Liljequist,David L. Paterson,Louis B. Rice,John Stelling,Marc Struelens,Alkiviadis Vatopoulos,J T Weber,Dominique L Monnet +17 more
A new antibiotic kills pathogens without detectable resistance
Losee Lucy Ling,Tanja Schneider,Aaron J. Peoples,Amy Spoering,Ina Engels,Brian P. Conlon,A. Mueller,Till F. Schäberle,Dallas Hughes,Slava S. Epstein,M. Jones,Linos Lazarides,Victoria Alexandra Steadman,Cohen Dr,Cintia R. Felix,Fetterman Ka,William Millett,Anthony Nitti,Ashley Zullo,Chao Chen,Kim Lewis +20 more